Cellular and molecular mechanisms of silibinin induces cell-cycle arrest and apoptosis on HeLa cells

Cell Biochemistry and Function

Volumn 30, Issue 3, 2012, Pages 243-248

  Zhang, Y ^a,b   Ge, Y ^a,b   Chen, Y ^a   Li, Q ^a   Chen, J ^c   Dong, Y ^c   Shi, W ^a  

^a JILIN UNIVERSITY   (China)

^b JILIN INSTITUTE OF CHEMICAL TECHNOLOGY   (China)

^c JIANGSU UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle arrest; Cervical cancer; Mechanism; Silibinin

Indexed keywords

CYCLIN DEPENDENT KINASE; DEATH RECEPTOR; SILIBININ;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL LINE; CONCENTRATION RESPONSE; DRUG MECHANISM; FEMALE; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; FEMALE; HELA CELLS; HUMANS; SIGNAL TRANSDUCTION; SILYMARIN; UTERINE CERVICAL NEOPLASMS;

EID: 84859440406     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1842     Document Type: Article

References (30)

1. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manage Care Pharm 2010; 16: 217-230.
2. Athol K. HPV vaccination and testing. Rev Obstet Gynecol 2010; 3: 33-34.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
4. Duan WJ, Li QS, Xia MY, et al. Silibinin activated p53 and induced autophagic death in human fibrosarcoma HT1080 cells via reactive oxygen species-p38 and c-Jun N-terminal kinase pathways. Biol Pharm Bull 2011; 34: 47-53.
5. Deep G, Agarwal R. Antimetastatic efficacy of Silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metast Rev 2010; 29: 447-463.
6. Singh RP, Dhanalakshmi S, Tyagi AK, et al. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002; 62: 3063-3069.
7. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 15: 465-489.
8. Agarwal C, Singh RP, Dhanalakshmi S, et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003; 22: 8271-8282.
9. Tyagi A, Agarwal C, Harrison G, et al. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 2004; 25: 1711-1720.
10. Lin CJ, Sukarieh R, Pelletier J. Silibinin inhibits translation initiation: implications for anticancer therapy. Mol Cancer Ther 2009; 8: 1606-1612.
11. Fu HY, Lin MZ, Katsumura Y, et al. Protective effects of silybin and analogues against X-ray radiation-induced damage. Acta Biochim Biophys Sin 2010; 42: 489-495.
12. Marco T, Alessandra C, Monika S, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009; 50: 1102-1111.
13. Garcia-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1α and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapySilibinin inhibits mTOR and HIF-1α. Oncogene 2009; 28: 313-324.
14. Fan S, Li LH, Chen SG, et al. Silibinin induced-autophagic and apoptotic death is associated with ROS and RNS increase in HeLa cells. Free Radic Res 2011; 1: 38-45.
15. Li L, Ge Y, Zhang LL, et al. Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett 2008; 272: 61-69.
16. Hogan FS, Krishnegowda NK, Mikhailova M, et al. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res 2007; 143: 58-65.
17. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmaco 2000; 60: 1051-1059.
18. Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 1994; 14: 2077-2086.
19. Wesierska-Gadek J, Gueorguieva M, Horky M. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol 2003; 55: 895-902.
20. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004; 5: 27-36.
21. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate 2001; 46: 98-107.
22. Fischer PM. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr Opin Drug Discov Devel 2001; 4: 623-634.
23. Venkateswaran V, Fleshner NE, Klotz LH. Modulation of cell proliferation and cell cycle regulators by vitamin e in human prostate carcinoma cell lines. J Urol 2002; 168: 1578-1582.
24. Singh RP, Dhanalakshmi S, Agarwal R. Phytochemicals as cell cycle modulators--a less toxic approach in halting human cancers. Cell Cycle 2002; 1: 156-161.
25. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495.
26. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001; 7: 95-106.
27. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002; 21: 8786-8803.
28. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-194.
29. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-49.
30. Arnoult D, Parone P, Martinou JC, et al. Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli. J Cell Bio 2002; 159: 923-929.